Stocktoria
CARDINAL HEALTH INC CAH
NYSE · stock · Wholesale-Drugs, Proprietaries & Druggists' Sundries · website · IPO 1983-08-04 · LEI
CARDINAL HEALTH INC financials (annual)
Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254.2B | $222.6B | $226.8B | $205.0B | $181.3B | $162.5B | $152.9B | $145.5B | $136.8B | $130.0B |
| Gross profit | $9.8B | $8.2B | $7.4B | $6.9B | $6.5B | $6.8B | $6.9B | $6.8B | $7.2B | $6.5B |
| SG&A expense | $6.1B | $5.4B | $5.0B | $4.8B | $4.5B | $4.5B | $4.6B | $4.5B | $4.6B | $3.8B |
| Operating income | $2.6B | $2.3B | $1.2B | $752.0M | -$607.0M | $472.0M | -$4.1B | $2.1B | $126.0M | $2.1B |
| Interest expense | $348.0M | $215.0M | $51.0M | $84.0M | $147.0M | $180.0M | $238.0M | $294.0M | $329.0M | $201.0M |
| Income tax | $469.0M | $532.0M | $348.0M | $332.0M | $153.0M | -$289.0M | -$79.0M | $386.0M | -$487.0M | $630.0M |
| Net income | $1.7B | $1.6B | $852.0M | $330.0M | -$938.0M | $611.0M | -$3.7B | $1.4B | $256.0M | $1.3B |
| EPS (diluted) | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 | $2.08 | $-12.61 | $4.53 | $0.81 | $4.03 |
| Operating cash flow | $5.2B | $2.4B | $3.8B | $2.8B | $3.2B | $2.4B | $2.0B | $2.7B | $2.8B | $1.2B |
| Free cash flow | $4.5B | $1.9B | $3.3B | $2.4B | $2.8B | $2.0B | $1.6B | $2.4B | $2.4B | $797.0M |
| Cash & equivalents | $4.9B | $3.9B | $5.1B | $4.1B | $4.7B | $3.4B | $2.8B | $2.5B | $1.8B | $6.9B |
| Inventory | $17.3B | $16.8B | $15.0B | $16.1B | $15.6B | $14.6B | $13.2B | $12.8B | $12.3B | $11.3B |
| Total assets | $57.3B | $53.1B | $45.1B | $43.3B | $43.9B | $44.5B | $40.8B | $41.0B | $40.0B | $40.1B |
| Shareholders' equity | -$2.9B | -$2.8B | -$3.2B | -$3.0B | -$882.0M | $1.8B | $1.8B | $6.3B | $6.1B | $6.8B |
Growth · year-over-year · Revenue CAGR 7.7%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +14.2% | -1.9% | +10.7% | +13.0% | +11.6% | +6.2% | +5.1% | +6.4% | +5.3% | +6.9% |
| Net income growth | +9.8% | +83.2% | +158.2% | — | -253.5% | — | -371.2% | +432.4% | -80.1% | -9.7% |
| EPS growth | +12.1% | +87.0% | +173.8% | — | -262.0% | — | -378.4% | +459.3% | -79.9% | -6.7% |
| Free cash flow growth | +144.6% | -43.1% | +37.6% | -15.2% | +37.4% | +28.0% | -33.8% | +0.4% | +199.1% | -68.2% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.